ArticleAIDS (London, England)2018
Benefits and harms of lung cancer screening in HIV-infected individuals with CD4+ cell count at least 500 cells/μl.
Article in AIDS (London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 49 citations in OpenAlex.
- Reducing Lung Cancer Disparities Calls for Another Look: Inclusion of Priority Populations in Screening Guidelines.Annals of the American Thoracic Society · 2025Article
- Natural history models for lung Cancer: A scoping review.Lung cancer (Amsterdam, Netherlands) · 2025Article
- The Use of a Tailored Decision Aid to Improve Understanding of Lung Cancer Screening in People With HIV.Chest · 2025Observational
- Adaptation of a Tailored Lung Cancer Screening Decision Aid for People With HIV.CHEST pulmonary · 2024Article
- State of the science and future directions for research on HIV and cancer: Summary of a joint workshop sponsored by IARC and NCI.International journal of cancer · 2024Review
- Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios in Distinguishing Lung Cancer in People with HIV.Disease markers · 2024Article
- The causal relationship between immune cells and hepatocellular carcinoma: a Mendelian randomization (MR).Ecancermedicalscience · 2024Article
- Comparison of Stage I Non-Small-Cell Lung Cancer Treatments for Patients Living With HIV: A Simulation Study.Clinical lung cancer · 2023Article
- Cancer screening in people living with HIV.Cancer medicine · 2023Review
- Lung cancer screening adherence among people living with and without HIV: An analysis of an integrated health system in Florida, United States (2012-2021).Preventive medicine reports · 2023Article
- Lung Cancer Screening in People With HIV: A Mixed-Methods Study of Patient and Provider Perspectives.American journal of preventive medicine · 2023Article
- HIV-associated lung disease.Nature reviews. Disease primers · 2023Review
- Trends and risk of lung cancer among people living with HIV in the USA: a population-based registry linkage study.The lancet. HIV · 2022Article
- Assessment of treatment strategies for stage I non-small cell lung cancer in patients with comorbidities.Lung cancer (Amsterdam, Netherlands) · 2022Article
- Optimizing the use of adjuvant chemotherapy in non-small cell lung cancer patients with comorbidities.Current problems in cancer · 2022Article
- Second primary malignancy risk after Hodgkin lymphoma treatment among HIV-uninfected and HIV-infected survivors.Leukemia & lymphoma · 2022Article
- Article
- Harm reduction for smokers living with HIV.The lancet. HIV · 2021Review
- The effect of non-AIDS-defining cancers on people living with HIV.The Lancet. Oncology · 2021Review
- Article
Corrections and comments
- Commented on by
Authors and funding
11 authors at 8 institutions in 2 countries.
Funding
Abstract
objectiveLung cancer is the leading cause of non-AIDS-defining cancer deaths among HIV-infected individuals. Although lung cancer screening with low-dose computed tomography (LDCT) is endorsed by multiple national organizations, whether HIV-infected individuals would have similar benefit as uninfected individuals from lung cancer screening is unknown. Our objective was to determine the benefits and harms of lung cancer screening among HIV-infected individuals.
designWe modified an existing simulation model, the Lung Cancer Policy Model, for HIV-infected patients. DATA SOURCES: Veterans Aging Cohort Study, Kaiser Permanente Northern California HIV Cohort, and medical literature. TARGET POPULATION: HIV-infected current and former smokers. TIME HORIZON: Lifetime. PERSPECTIVE: Population.
interventionAnnual LDCT screening from ages 45, 50, or 55 until ages 72 or 77 years.
main outcome measuresBenefits assessed included lung cancer mortality reduction and life-years gained; harms assessed included numbers of LDCT examinations, false-positive results, and overdiagnosed cases. RESULTS OF BASE-CASE ANALYSIS: For HIV-infected patients with CD4 cell count at least 500 cells/μl and 100% antiretroviral therapy adherence, screening using the Centers for Medicare & Medicaid Services criteria (age 55-77, 30 pack-years of smoking, current smoker or quit within 15 years of screening) would reduce lung cancer mortality by 18.9%, similar to the mortality reduction of uninfected individuals. Alternative screening strategies utilizing lower screening age and/or pack-years criteria increase mortality reduction, but require more LDCT examinations. LIMITATIONS: Strategies assumed 100% screening adherence.
conclusionLung cancer screening reduces mortality in HIV-infected patients with CD4 cell count at least 500 cells/μl, with a number of efficient strategies for eligibility, including the current Centers for Medicare & Medicaid Services criteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.